Gynac 2. Cancer Cervix Flashcards
Endocervix : -
- Lies close to:-
- Lined by :-
- Colour :-
547
Exocervix
- Part of cervix that lies :-
- Lined by :-
- Colour :-
547
External os :- Part where cervix :- Shape 1. :- 2. :-
547
Transformation zone
- Junction :-
- Dynamic point : -
- Lies at the level of :-
Trnaspformation zone movies outward ( toward cervix ) under 3 Ps
Moves inward when there’s no :-
I.e :-
547-548
Classification of transformation zone :-
Type 1 :-
Type 2 :-
Type 3 :-
Colour :-
548
Cancer cervix
MC cancer of cervix :-
MC site of cancer cervix :-
MC site of adenocarcinoma cervix :-
548
Lymphatic drainage of cervix :- H O P E
MC LN involved in CA cervix :-
Sentinal LN for CA cervix :-
Superficial LN in CA cervix :-
548
Pathogenesis of CA cervix
- Metaplasia :-
- Dysplasia :-
Classification of dysplasia CIN :- CIN 1 :- CIN 2 :- CIN 3 :- Cancer in situ :- Invasive cancer cervix :-
549
Bethesda classification:-
CIN 1 :-
CIN 2 :-
CIN 3 :-
Cancer in situ :-
Note :- dysplastic cells :-
549
Cancer cervix risk factor Most important :- Increase chances of inf in :- Other 1. 2. 3. OCP causes :- 4. Exposer to :-
550
Human papilloma virus :-
- Viral protein required
a. For attachment:-
b. For viral replication :-
c. For malignancy:-
E6 :- suppresses :-
E7:- suppresses :-
551
Diagnosis of HPV :- ,,,,,,,,,
- ( best )
Done in female :-
551
HPV subtypes :-
551
One liner MC HPV associated with cancer cervix :- MC HPV associated with SCC of cervix :- Most specific HPV for CA cervix :- MC HPV asso with adenocarcinoma cervix :-
551
Bivalent vaccine :- Brand :- HPV subtype :- Protect against:- Dosage schedule:- Route :- Administrated to :- Adjuent :-
552
Quadrivalent vaccine
Brand :- HPV subtype :- Protect against:- Dosage schedule:- Route :- Administrated to :- Adjuent :-
552
9 valent
Brand :- HPV subtype :- Protect against:- Dosage schedule:- Route :- Administrated to :- Adjuent :-
552
Age of vaccine administration:- Ideal age :- MC complication :- Contraindication 1. 2. 3.
553
MC age group of HPV inf :- MC sexually transmitted disease ( std ) in usa :- MC age for CIN :- Cancer in situ :- Cancer cervix :-
553
Diagnosis of CA cervix :-
Screening test
- Rural area :-
Diagnostic test :-
1.
2.
553
Pap smear Age to start :- Instruments :- image 1. 2. Sample site Slide 1:- To detect Slide 2 :- To detect Slide 3 :- From
Images :-
554
Sample site for cytology ( Pap smear ) :-
Sample site for hormone study :-
Fixative used in :-
555
Liquid based cytology
1. Instrument:-
2. Ficpxative :-;
3.
555
Guidelines for Pap smear :-
1. Start pap smear at:- ,,,,,,,,,
Repeat every :-
Till women becomes :-
From age ,,,,to ,,,yr of age :- ,,,,,,,,,l+ ,,,,,,,,
Done every :-
Or continue :-556
- Stop Pap smear at :- ,,,,, years age
Criteria to stop:-
1. :-
2.:- - HIV positive female :-
Screening every :-
Uncertain to stop :- - Female treated for
Continue for :- - If female has taken HPV vaccine :
:-
556
VIA:-
Dysplasia +ve colour : -
Normal :-
556
VILI
Dysplasia +ve colour :-
Unstained reason :-
Normal :-
556
Report or action of Pap smear :- Report 1 :- Report 2 :- Report 3 :- Report 4 :- Report 5 :- Report 6 :- Report 7 :- Report 8 :-
557
Report 3 :- ,,,,,, Pap can detect inf 1. 2. 3. 4. 5. Pap smear can not detect :- 1. 2.
557
Report 4 :-
ASCUS :-
% ,,,,,to convert in ,,,,,,,
- Age 21-24 :- ,,,,,,,,
- Age > 25 :-
557
Report 5 :-
LSIL
1. :-
2. :-
In case of HSIL :- growth not visible :-
558
LSIL in female ( 21-24 ) :-
Follow up with :-
Contraindicated:-
LSIL in post menopausal :-
LSIL in pregnant female :-
In HSIL :-
558
Other report and action of Pap smear :-
- Pap :- normal , but HPV DNA is positive :-
Repeat:-
Persist
Do :-
559
Report 6 :-
% of conversion :-
HPE cannot exclude :-
Do :-
559
Report 7
Lesion visible :-
Lesion not visible :-
559
Report 8 :-
Suggest :-
Test done :-
559
